查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1463137

化療引起的中性粒細胞減少症治療市場、佔有率、規模、趨勢、行業分析報告：依治療、依分銷管道、依地區

Chemotherapy Induced Neutropenia (CIN) Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment, Distribution Channel; By Region; Segment Forecast, 2024- 2032
出版日期: | 出版商: Polaris Market Research | 英文 114 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的最新研究，預計到 2032 年，全球化療引起的中性粒細胞減少症治療市場規模將達到 7.7584 億美元。 該研究報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

全球癌症發生率的增加是化療引起的中性粒細胞減少症 (CIN) 治療市場的關鍵驅動因素。 癌症發生率上升的主要原因是人口快速老化。 由於基因突變、免疫系統減弱、長期接觸致癌物質、DNA修復機制受損、荷爾蒙波動以及與年齡相關的慢性疾病等多種因素，老齡化人群更容易患癌症。

不健康的生活習慣，例如吸菸、久坐習慣、不良飲食習慣和過量飲酒，進一步導致全球癌症發生率上升。 癌症仍然是世界上最主要的死亡原因，光在 2020 年就奪走了約 1,000 萬人的生命，幾乎佔死亡人數的六分之一。 最常見的癌症類型是乳癌（226萬人）、肺癌（221萬人）、大腸癌（193萬人）、攝護腺癌（141萬人）和皮膚癌（120萬人）。人）。 此外，每年約有 40 萬名兒童被診斷出罹患癌症。

化療引起的中性粒細胞減少症 (CIN) 通常是化療的副作用，它會減少中性粒細胞的數量，中性粒細胞是對抗感染所必需的一種白血球。 化療藥物會幹擾骨髓產生嗜中性球的能力，削弱免疫系統並增加感染的可能性。 CIN 常導致治療延遲和化療劑量減少，影響治療效果。

經歷 CIN 的患者發生嚴重感染並需要住院治療的風險增加。 因此，仔細監測和適當管理化療引起的中性粒細胞減少症對於最大限度地減少併發症和優化癌症治療至關重要。 這凸顯了對有效解決 CIN 的客製化治療方法的需求不斷增長。

全球癌症發生率的上升導致接受化療的患者人數增加，從而導致對化療引起的中性粒細胞減少症 (CIN) 的有效治療的需求增加。 需求激增預計將成為市場成長的主要催化劑。 此外，化療方案的進步，包括引入更有效的標靶療法，正在提高癌症治療的有效性。 然而，這些發展也增加了 CIN 的風險。 因此，迫切需要製定改進的策略來預防和管理化療患者中性粒細胞減少症。

化療引起的中性粒細胞減少症治療市場報告亮點

G-CSF製劑作為黃金標準治療藥物獲得最大佔有率

醫院藥局憑藉完善的設備和外科醫生佔市場主導地位

由於癌症患者數量的增加和化療的使用，亞太地區預計將錄得強勁增長率

主要市場參與者包括艾伯維 (AbbVie)、Coherus BioSciences、葛蘭素史克 (GlaxoSmithKline)、Lupin、G1 Therapeutics、默克 (Merck)、諾華 (Novartis) 和 Spectrum Pharmaceuticals。

目錄

第一章簡介

第 2 章執行摘要

第三章研究方法

第 4 章全球化療引起的中性粒細胞減少症 (CIN) 治療市場洞察

  • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 產業快照
  • 化療引起的中性粒細胞減少症 (CIN) 治療市場動態
    • 推動者和機會
      • 癌症患者數量不斷增加，並且越來越多地使用化療作為治療選擇
      • 化療引起嗜中性白血球減少症的可能性增加
    • 抑制因素和課題
      • 治療費用飆漲和監管政策嚴格
  • 杵分析
  • 化療引起的中性粒細胞減少症 (CIN) 治療行業的趨勢
  • 價值鏈分析
  • 新冠肺炎 (COVID-19) 影響分析

第 5 章化療引起的中性粒細胞減少症 (CIN) 治療的全球市場（依治療類型劃分）

  • 主要發現
  • 簡介
  • 抗生素治療
  • 粒細胞集落刺激因子療法 (G-CSF)
  • 粒細胞輸注
  • 其他

第 6 章全球化療引起的中性粒細胞減少症 (CIN) 治療市場（依分銷管道）

  • 主要發現
  • 簡介
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 7 章全球化療引起的中性粒細胞減少症 (CIN) 治療市場（依地區）

  • 主要發現
  • 簡介
    • 2019-2032 年化療引起的中性粒細胞減少症 (CIN) 治療市場評估（依地區）
  • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 北美
    • 北美：化療引起的中性粒細胞減少症 (CIN) 治療市場，依分銷管道劃分，2019-2032 年
    • 北美：化療引起的中性粒細胞減少症 (CIN) 治療市場（依治療類型），2019-2032 年
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 美國
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 加拿大
  • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 歐洲
    • 歐洲：化療引起的中性粒細胞減少症 (CIN) 治療市場（依分銷管道），2019-2032 年
    • 歐洲：2019-2032 年化療引起的中性粒細胞減少症 (CIN) 治療市場（依治療類型）
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 英國
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 法國
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 德國
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 義大利
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 西班牙
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 荷蘭
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 俄羅斯
  • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 亞太地區
    • 亞太地區：化療引起的中性粒細胞減少症 (CIN) 治療市場（依分銷管道），2019-2032 年
    • 亞太地區：2019-2032 年化療引起的中性粒細胞減少症 (CIN) 治療市場（依治療類型）
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 中國
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 印度
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 馬來西亞
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 日本
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 印度尼西亞
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 韓國
  • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 中東和非洲
    • 中東和非洲：化療引起的中性粒細胞減少症 (CIN) 治療市場（依分銷管道），2019-2032 年
    • 中東和非洲：2019-2032 年化療引起的中性粒細胞減少症 (CIN) 治療市場（依治療類型）
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 沙烏地阿拉伯
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 阿聯酋
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 以色列
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 南非
  • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 拉丁美洲
    • 拉丁美洲：化療引起的中性粒細胞減少症 (CIN) 治療市場（依分銷管道），2019-2032 年
    • 拉丁美洲：2019-2032 年化療引起的中性粒細胞減少症 (CIN) 治療市場（依治療類型）
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 墨西哥
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 巴西
    • 化療引起的中性粒細胞減少症 (CIN) 治療市場 - 阿根廷

第八章競爭態勢

  • 擴張與收購分析
    • 放大
    • 收購
  • 合作/協作/合約/展覽

第九章公司簡介

  • AbbVie Inc.（Allergan PLC）
  • Aurobindo Pharma
  • Coherus BioSciences
  • GlaxoSmithKline PLC.
  • Lupin, G1 Therapeutics, Inc
  • Merck & Co., Inc
  • Novartis AG
  • Spectrum Pharmaceuticals
Product Code: PM4799

The global chemotherapy induced neutropenia treatment market size is expected to reach USD 775.84 million by 2032, according to a new study by Polaris Market Research. The report "Chemotherapy Induced Neutropenia (CIN) Treatment Market Share, Size, Trends, Industry Analysis Report, by Treatment (Antibiotic Therapy, Granulocyte Colony-Stimulating Factor Therapy, Granulocyte Transfusion, and Others), Distribution Channel; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing global incidence of cancer serves as a significant driver for the chemotherapy-induced neutropenia (CIN) treatment market. A major contributing factor to the rising cancer rates is the rapidly expanding aging population. The aging demographic is more susceptible to cancer due to various factors such as genetic mutations, weakened immune systems, prolonged exposure to carcinogens, impaired DNA repair mechanisms, hormonal fluctuations, and age-related chronic ailments.

Unhealthy lifestyle behaviours, including tobacco consumption, sedentary habits, poor dietary choices, and excessive alcohol intake, further contribute to the escalating cancer incidence worldwide. Cancer remains a leading cause of death globally, claiming nearly 10 Mn lives in 2020 alone, which accounts for nearly one in six deaths. The most prevalent cancer types include breast cancer (2.26 Mn cases), lung cancer (2.21 Mn), colon and rectal cancer (1.93 Mn cases), prostate cancer (1.41 Mn), skin cancer (1.20 Mn), and stomach cancer (1.09 Mn). Additionally, approximately 400,000 children are diagnosed with cancer annually.

Chemotherapy-induced neutropenia (CIN) commonly occurs as a side effect of chemotherapy, wherein the number of neutrophils, a type of white blood cell vital for combating infections, decreases. Chemotherapy medications hinder the bone marrow's ability to generate neutrophils, weakening the immune system and heightening vulnerability to infections. CIN often leads to treatment delays or reductions in chemotherapy dosage, impacting treatment effectiveness.

Patients experiencing CIN face a heightened risk of developing severe infections, necessitating hospitalization. Consequently, careful monitoring and appropriate management of chemotherapy-induced neutropenia are essential to minimize complications and optimize cancer treatment delivery. This underscores the increasing demand for tailored treatment approaches to address CIN effectively.

The rising global cancer rates have necessitated a larger cohort of patients undergoing chemotherapy, consequently escalating the demand for efficient management of chemotherapy-induced neutropenia (CIN). This surge in demand is anticipated to serve as a primary catalyst for the growth of the market. Furthermore, advancements in chemotherapy protocols, including the introduction of more potent and targeted therapies, have enhanced cancer treatment efficacy. However, these developments have concurrently heightened the risk of CIN. Consequently, there is an increased urgency to develop improved strategies for the prevention and management of neutropenia in chemotherapy patients.

Chemotherapy Induced Neutropenia Treatment Market Report Highlights

G-CSF segment garnered the largest share, as it is considered as gold standard treatment option

Hospital pharmacies dominated the market, as they are fully equipped with the facilities and surgeons

APAC expected to register robust growth rate, owing to the rise in cancer cases and use of chemotherapy

The key market players include AbbVie, Coherus BioSciences, GlaxoSmithKline, Lupin, G1 Therapeutics, Merck, Novartis, and Spectrum Pharmaceuticals

Polaris Market Research has segmented the chemotherapy induced neutropenia treatment market report based on treatment type, distribution channel, and region:

Chemotherapy Induced Neutropenia Treatment Market, Type Outlook (Revenue - USD Million, 2023 - 2032)

  • Antibiotic Therapy
  • Granulocyte Colony-Stimulating Factor Therapy (G-CSF)
  • Granulocyte Transfusion
  • Others

Chemotherapy Induced Neutropenia Treatment Market, Distribution Channel Outlook (Revenue - USD Million, 2023 - 2032)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Chemotherapy Induced Neutropenia Treatment Market, Regional Outlook (Revenue - USD Million, 2023 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Rest of Asia Pacific
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market Insights

  • 4.1. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Industry Snapshot
  • 4.2. Chemotherapy Induced Neutropenia (CIN) Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising cases of cancer and increasing use of chemotherapy as treatment option
      • 4.2.1.2. Rising likelihood of chemotherapy induced neutropenia
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment and stringent regulatory policies
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Chemotherapy Induced Neutropenia (CIN) Treatment Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment, by Treatment Type, 2019-2032 (USD Million)
  • 5.3. Antibiotic Therapy
    • 5.3.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Antibiotic Therapy, by Region, 2019-2032 (USD Million)
  • 5.4. Granulocyte Colony-Stimulating Factor Therapy (G-CSF)
    • 5.4.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Granulocyte Colony-Stimulating Factor Therapy (G-CSF), by Region, 2019-2032 (USD Million)
  • 5.5. Granulocyte Transfusion
    • 5.5.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Granulocyte Transfusion, by Region, 2019-2032 (USD Million)
  • 5.6. Others
    • 5.6.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Others, by Region, 2019-2032 (USD Million)

6. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Hospital Pharmacies, by Region, 2019-2032 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Retail Pharmacies, by Region, 2019-2032 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Online Pharmacies, by Region, 2019-2032 (USD Million)

7. Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • 7.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - North America
    • 7.3.1. North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.3.2. North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.3.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - U.S.
      • 7.3.3.1. U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.3.3.2. U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.3.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Canada
      • 7.3.4.1. Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.3.4.2. Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Europe
    • 7.4.1. Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.4.2. Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - UK
      • 7.4.3.1. UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.3.2. UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - France
      • 7.4.4.1. France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.4.2. France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Germany
      • 7.4.5.1. Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.5.2. Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Italy
      • 7.4.6.1. Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.6.2. Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Spain
      • 7.4.7.1. Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.7.2. Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.8. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Netherlands
      • 7.4.8.1. Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.8.2. Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.4.9. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Russia
      • 7.4.9.1. Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.4.9.2. Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Asia Pacific
    • 7.5.1. Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.5.2. Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - China
      • 7.5.3.1. China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.3.2. China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - India
      • 7.5.4.1. India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.4.2. India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Malaysia
      • 7.5.5.1. Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.5.2. Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Japan
      • 7.5.6.1. Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.6.2. Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Indonesia
      • 7.5.7.1. Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.7.2. Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.5.8. Chemotherapy Induced Neutropenia (CIN) Treatment Market - South Korea
      • 7.5.8.1. South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.5.8.2. South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.6.2. Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.3.2. Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - UAE
      • 7.6.4.1. UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.4.2. UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Israel
      • 7.6.5.1. Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.5.2. Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.6.6. Chemotherapy Induced Neutropenia (CIN) Treatment Market - South Africa
      • 7.6.6.1. South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.6.6.2. South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • 7.7. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Latin America
    • 7.7.1. Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
    • 7.7.2. Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.3. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Mexico
      • 7.7.3.1. Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.3.2. Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.4. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Brazil
      • 7.7.4.1. Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.4.2. Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
    • 7.7.5. Chemotherapy Induced Neutropenia (CIN) Treatment Market - Argentina
      • 7.7.5.1. Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
      • 7.7.5.2. Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. AbbVie Inc. (Allergan PLC)
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Aurobindo Pharma
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Coherus BioSciences
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. GlaxoSmithKline PLC.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Lupin, G1 Therapeutics, Inc
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Merck & Co., Inc
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Novartis AG
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. Spectrum Pharmaceuticals
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development

List of Tables

  • Table 1 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 2 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 3 Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Table 4 North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 5 North America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 6 U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 7 U.S.: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 8 Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 9 Canada: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 10 Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 11 Europe: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 12 UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 13 UK: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 14 France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 15 France: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 16 Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 17 Germany: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 18 Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 19 Italy: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 20 Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 21 Spain: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 22 Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 23 Netherlands: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 24 Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 25 Russia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 26 Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 27 Asia Pacific: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 28 China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 29 China: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 30 India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 31 India: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 32 Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 33 Malaysia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 34 Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 35 Japan: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 36 Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 37 Indonesia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 38 South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 39 South Korea: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 40 Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 41 Middle East & Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 42 Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 43 Saudi Arabia: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 44 UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 45 UAE: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 46 Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 47 Israel: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 48 South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 49 South Africa: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 50 Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 51 Latin America: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 52 Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 53 Mexico: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 54 Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 55 Brazil: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)
  • Table 56 Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2019-2032 (USD Million)
  • Table 57 Argentina: Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2019-2032 (USD Million)

List of Figures

  • Figure 1 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, 2019-2032 (USD Million)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by Distribution Channel
  • Figure 7 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Distribution Channel, 2022 & 2032 (USD Million)
  • Figure 8 Market by Treatment Type
  • Figure 9 Global Chemotherapy Induced Neutropenia (CIN) Treatment Market, by Treatment Type, 2022 & 2032 (USD Million)
  • Figure 10 Chemotherapy Induced Neutropenia (CIN) Treatment Market Assessment, By Geography, 2019-2032 (USD Million)
  • Figure 11 Strategic Analysis - Chemotherapy Induced Neutropenia (CIN) Treatment Market